Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases.
Namboodiri
Haridasan V
HV
Department of Biology, Locus Pharmaceuticals, Inc, Four Valley Square, 512 East Township Line Rd,Blue Bell, Pennsylvania 19422, USA. vnamboodiri@ansarisbio.com
Bukhtiyarova
Marina
M
Ramcharan
Joseph
J
Karpusas
Michael
M
Lee
Younghee
Y
Springman
Eric B
EB